SCHEDULE 13G/A: Eventide Asset Management and Affiliates Disclose 3.46% Passive Stake in Inozyme Pharma

Eventide Asset Management, LLC, along with Finny Kuruvilla, M.D., Ph.D., and Robin C. John, have filed an amended Schedule 13G disclosing a combined beneficial ownership of 3.46% of Inozyme Pharma, Inc.'s common stock as of December 31, 2024.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Inozyme Pharma, Inc.
• As of December 31, 2024, each reporting person beneficially owned 2,220,000 shares of Inozyme Pharma, Inc. Common Stock.
• This aggregate amount represents 3.46% of the class of Inozyme Pharma, Inc.'s Common Stock.
• Eventide Asset Management, LLC holds sole voting power and sole dispositive power over all 2,220,000 shares.
• Finny Kuruvilla, M.D., Ph.D., and Robin C. John each hold shared voting power and shared dispositive power over the same 2,220,000 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The document is a routine regulatory disclosure of beneficial ownership and does not contain specific information that would be categorized as positive regarding the issuer's business operations or financial performance.

Negatives

• The document is a routine regulatory disclosure of beneficial ownership and does not contain specific information that would be categorized as negative regarding the issuer's business operations or financial performance.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Inozyme Pharma, Inc., mitigating the risk of an activist investor seeking control from this group.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Inozyme Pharma, Inc.'s future outlook.

Industry Context

This document is a standard regulatory filing disclosing passive ownership and does not provide specific analysis of how Inozyme Pharma, Inc. relates to broader industry trends or competitors.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes in the company, confirming that a notable investment firm and individuals hold a position.

Next Steps

• The reporting persons will file further amendments to this Schedule 13G if there are material changes to their beneficial ownership or the purpose of their holdings.

Key Dates

Keywords

Inozyme Pharma, Eventide Asset Management, Schedule 13G, beneficial ownership, common stock, SEC filing, passive investment, investment firm, biotechnology, pharmaceuticals